Subscribe for email alerts

Don’t miss a single Science & Enterprise post. Sign up for our daily email alerts.

Donate to Science & Enterprise

Please share Science & Enterprise

Immune Disease Biotech Acquired in $405M Deal

Human T-cell

A biotechnology developer of treatments for autoimmune disorders with checkpoint receptor proteins is acquired by drug maker Gilead Sciences. . . . → Read More: Immune Disease Biotech Acquired in $405M Deal

Ginkgo Acquires Biomaterials Maker as Industry Consolidates

Digital DNA

A developer of synthetic biology tools and components is acquiring a biological materials developer for its automation assets as the biotechnology industry consolidates. . . . → Read More: Ginkgo Acquires Biomaterials Maker as Industry Consolidates

Diabetes Cell Therapy Biotech Acquired in $320M Deal

Diabetes word cloud

A developer of therapies derived from stem cells to replace malfunctioning islet cells in people with type 1 diabetes was acquired by Vertex Pharmaceuticals. . . . → Read More: Diabetes Cell Therapy Biotech Acquired in $320M Deal

GSK Acquires Advanced Vaccine Biotech in $3.3B Deal

Streptococcus pneumoniae bacteria

Drug maker GSK is buying a biotechnology company developing vaccines for respiratory and infectious diseases that generate multiple immune responses. . . . → Read More: GSK Acquires Advanced Vaccine Biotech in $3.3B Deal

Partnership Developing Faster, Sensitive Covid-19 Test

SARS-CoV-2 and cell

A collaboration between developers of protein analytics and test-strip diagnostics aims to create a quicker, more sensitive, easy-to-use Covid-19 detection test. . . . → Read More: Partnership Developing Faster, Sensitive Covid-19 Test

Digital Mental Therapy Company to Go Public in Merger

Child with computer tablet

A creator of game therapies for cognitive impairments is becoming a publicly-traded company through a special purpose acquisition company or SPAC. . . . → Read More: Digital Mental Therapy Company to Go Public in Merger

Novo Nordisk Buys RNA Biotech in $3.3B Deal

Wall Street sign

Global drug maker Novo Nordisk is acquiring biotechnology company Dicerna Pharmaceuticals Inc. in an all-cash deal valued at $3.3 billion. . . . → Read More: Novo Nordisk Buys RNA Biotech in $3.3B Deal

Synthetic Antibody Company Goes Public in $230M Merger

Four fist bump

A developer of synthetic antibodies for inflammatory and skin disorders is becoming a public company through a special purpose acquisition-merger. . . . → Read More: Synthetic Antibody Company Goes Public in $230M Merger

RNA Manufacturer Goes Public in $282M Merger

Bumble bee and flower

A company producing synthetic RNA for agricultural and biomedical applications is now a public company after a special-purpose acquisition. . . . → Read More: RNA Manufacturer Goes Public in $282M Merger

Protein Chemistry Biotech Acquired in $2B Deal

DNA analysis graphic

Drug maker Bayer is acquiring a company discovering new therapies with a technology that reveals complex protein targets considered difficult to address. . . . → Read More: Protein Chemistry Biotech Acquired in $2B Deal